

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7

### Enhanced Chemotaxis of T-Lymphocytes from 825T Allele Carriers




Fig. 8






Fig. 9

**Time to AIDS**

AIDS is defined as AIDS-defining disorders or CD4 count &lt; 200




Fig. 10

**Event: CD4 Cell Count Below 200 per  $\mu$ l**




Fig. 11


**Event: Lowest CD4 Cell Count**

Fig. 12

**Event: Time to maximum HIV Virus Load**

Virus Copy Number determined by Quantitative PCR




Fig. 13




Fig. 14

# Potential Structures of G $\beta$ 3 and G $\beta$ 3s / G $\beta$ 3s-2




Fig. 15


i SP9 Cells  
varianten

Fig. 16






FIG. 17 B3-original sequence of Levine. The exons are underlined alternately. The area which is omitted by cryptic splice as bold-faced.

1 gggtcgATGG GGGAGATGGA GCAACTCGGT CAGGAAGCGG AGCAGCTCAA GAAGCAGATT  
 Start-ATG EXON 3 after Ansari-Lari  
 Nucleotide 1-6 seem not to be affected

61 GCAGATGCCA GGAAGCCTG TGCTGACGTT ACTCTGGCAG AGTGGTGTTC TGSCCTAGAG  
 /Beginning EXON 4 /EXON 5 Beginning  
 ==> ENDE 1 KLON ANSARI

121 GTGGTGGGAC GAGTCCAGAT GCGGACGCGG CGGACGTTAA GGGGACACCT GGCCAAGATT  
 EXON 5

181 TACGCCATGC ACTGGGCCAC TGATTTCTAAG CTGCTGGTAA GTGCTCTGCA AGATGGGAG  
 EXON 5 / Beginning EXON 6

241 CTGATCGTGT GGGACAGCTA CACCACCAAC AAGGTGCACG CCATCCCACT GCGCTCTCTC  
 EXON 6 / EXON 7

301 TGGGTCATGA CCTGTGCCTA TGCCCCATCA GGGAACTTTG TGGCATGTGG GGGGCTGGAC  
 EXON 7

361 AACATGTGTT CCATCTACAA CCTCAATCC CGTGAGGCA ATGTCAAGST CAGCCGGGAG  
 EXON 7

421 CTTTCTGCTC ACACAGTTA TCTCTCTGTC TGCCGCTTCC TGATGACAA CAATATTGTG  
 EXON 7 /EXON 8

481 ACCAGCTCGG GGGACACCAC GTGTGCTTTG TGGACATTG AGACTGGGCA GCAGAAGACT  
 EXON 8 /EXON 9

cryptic SPLICING

541 CTATTGTGG GACACAGGG TGACTGCATG AGCCTGGCTG TGTCTCTGA CTTCAATCTC  
 EXON 9  
 cryptic SPLICING

601 TTCAATTTGG GGGCCTGTGA TGCCAGTGCC AAGCTCTGGG ATGTGCGAGA GGGGACCTGC  
 EXON 9  
 cryptic SPLICING /

661 CGTCAGACTT TCACGTGCCA CGAGTCGGAC ATCAAGGCCA TCTGTTCTT CCCCAGTGA  
 EXON 9 / Beginning EXON 10

721 GAGGCCATCT GCACGGGCTC GGATGACGCT TCCTGCGCTT TGTTGACCT GCGGCGAGC  
 EXON 10

781 CAGGAGCTGA TCTGCTTCTC CCACGAGAGC ATCATCTGCG GCATCAGCTC CGTGCGCTTC  
 EXON 10 Polymorphism site aegtc tgt

841 TCCTCAGTGG GCGCGTACTT ATTGCTGGC TACGACGACT TCAACTGCAA TGCTTGGGAC  
 EXON 10

901 TCCATGAAGT CTGAGCGTGT GGGCATCTCT TCTGGCCACG ATACAGGGT GAGCTGCTGC  
 EXON 10 /Beginning EXON 11

961 GGAGTCACAG CTGACGGGAT GGCTGTGGCC ACAGGTTCTT GGGACAGCTT CCTCAAAATC  
 EXON 11

1021 TGGAACCTGag gaggtggag aaagggaggt ggaaggcagt gaacacactc agcagccccc  
 EXON 11  
 End of Open Reading Frame

1081 tgcgcgaccc catctcattc aggtgttttc ttctatatcc cgggtgccat tcccactaag  
 EXON 11

1141 ctttctcttt taagggcagt ggggagcatg ggaactgtgc ttggggaggc agcatcaggg  
 EXON 11

1201 acacaggggc aaagaactgc cccatctctc cccatggcct tccctcccca cagtcctcac  
 EXON 11  
 1261 agcctctccc ttaatgagca aggacaacct gccctccccc agccctttgc aggccagca  
 EXON 11  
 1321 gacttgagtc tgaggcccca ggccttagga ttctccccc aagaccacta ctttgtcca  
 EXON 11  
 1381 ggcctgggtg gtatagggcg ttggccctg tgactatggc tctggcaca ctagggtcct  
 EXON 11  
 1441 ggcctctctc ttattcatgc ttctccttt ttctacottt tttctctcc taagacacct  
 EXON 11  
 1501 gcaataaagt gtagcacct ggt  
 EXON 11 POLY A SITE

1381 ggcctgggtg gtatagggcg ttggccctg tgactatggc tctggcaca ctagggtcct  
 EXON 11

tctggcaca cta

1201 1261 1321 1381 1441 1501

Fig. 18 Sequence with two polymorphisms (Numbering after the Levine sequence)

gggtcgtatgg	gggagatgga	gcaactgcgt	caggaagcgg	agcagctcaa	gaagcagatt	60
gcagatgccca	ggaaagcctg	tgctgacgtt	actctggcag	agctgggtgtc	tggcctagag	120
gtggtgggac	gagtcacgat	gcggacgcgg	cggacgttaa	ggggacacct	ggccaagatt	180
tacgccatgc	actgggccac	tgattctaa	ctgctggtaa	gtgcctcgca	agatgggaag	240
ctgatcgtgt	gggacagcta	caccaccaac	aaggtgcaog	ccatccact	gcgtcctcc	300
tgggtcatga	cctgtgccta	tgccccatca	gggaactttg	tggcatgtgg	ggggctggac	360
aacatgtgtt	ccatctacaa	cctcaaatcc	cgtgaggcca	atgtcaaggt	cagccgggag	420
ctttctgctc	acacaggtta	tctctcctgc	tgccgcttcc	tggatgacaa	caatatgttg	480
accagctcgg	gggacaccac	gtgtgccttg	tgggacattg	agactgggca	gcagaagact	540
gtattttgtg	gacacacggg	tgactgcatg	agcctggctg	tgtctcctga	cttcaatctc	600
ttcatattcg	gggcctgtga	tgccagtgcc	aagctctggg	atgtgcgaga	ggggacctgc	660
cgtcagactt	tcaactggcca	cgagtcggac	atcaacgccca	tctgtttctt	ccccaatgga	720
gaggccatct	gcacgggctc	ggatgacgct	tcctgccgct	tgtttgacct	gcgggcagac	780
caggagctga	tctgtctctc	ccacgagagc	atcatctgcg	gcatacgtc	tgtggccttc	840
tcctcagtg	gcgcctact	attcgcggc	tacgacgact	tcaactgcaa	tgtctgggac	900
tccatgaagt	ctgagcgtgt	gggcatcctc	tctggccacg	ataacagggt	gagctgcctg	960
ggagtacag	ctgacgggat	ggctgtggcc	acaggttcc	gggacagctt	cctcaaaatc	1020
tggaaactgag	gaggctggag	aaagggaagt	ggaaggcagt	gaacacactc	agcagccccc	1080
tgccccagacc	catctcatc	aggtgttctc	ttctatatcc	cgggtgccat	tcccactaag	1140
ctttctcctt	tgagggcagt	ggggagcatg	ggactgtgcc	tttggggagc	agcatcaggg	1200
acacaggggc	aaagaaactgc	ccatctcct	ccatggcct	tcctcccca	cagtctcac	1260
agcctctccc	ttaatgagca	aggacaaact	gccccctccc	agccctttgc	aggcccagca	1320
gacttgagtc	tgaggcccca	ggccctagga	ttcctccccc	agagccacta	cctttgtcca	1380
tctggcacta	ctaggcctgg	gtggtatagg	gcgtttggcc	ctgtgactat	ggctctggca	1440
ccactagggt	cctggccctc	ttcttattca	tgtcttctcc	ttttctaccc	ttttttcttc	1500
tcctaagaca	cctgcaataa	agtgtagcac	cctgggt			1536

1 gggtcgATGG GGGAGATGGA GCAACTGCGT CAGGAAGCGG AGCAGCTCAA GAAGCAGTAA  
Start-ATG EXON 3  
Nucleotide 1-6 seem not to be affected

61 GCAGATGCCA GGAAAGCCTG TGCTGACGTT ACTCTGGCAG AGCTGGTGTG TGGCCTAGAG  
/Beginn EXON 4 /EXON 5 Beginning

121 GTGCTGGGAC GAGTCCAGAT GCGGACGCGG CGGACGTTAA GGGGACACCT GGCCAAGATT  
EXON 5

181 TACGCCATGC ACTGGGCCAC TGATTCTAAG CTGCTGGTAA GTGCCTCGCA AGATGGGAAG  
EXON 5 / Beginning EXON 6

241 CTGATCGTGT GGGACAGCTA CACCACCAAC AAGSTGACAG CCATCCCACT GCGCTCCTCC  
EXON 6 / EXON 7

301 TGGGTTCATGA CCTGTGCCTA TGCCCCATCA GGGAACTTTG TGGCATGTGG GGGGCTGGAG  
EXON 7

361 AACATGTGTT CCATCTACAA CCTCAAATCC CGTAGGGGCA ATGTCAAGGT CAGCCGGGAG  
EXON 7

421 CTTTCTGCTC ACACAGGTTA TCTCTCTGCG TGCCGCTTCC TGGATGACAA CAATATTGTG  
EXON 7 /EXON 8

1 gggtcgATGG GGGAGATGGA GCAACTGCGT CAGGAAGCGG AGCAGCTCAA GAAGCAGTAA  
Start-ATG EXON 3  
Nucleotide 1-6 seem not to be affected

61 GCAGATGCCA GGAAAGCCTG TGCTGACGTT ACTCTGGCAG AGCTGGTGTG TGGCCTAGAG  
/Beginn EXON 4 /EXON 5 Beginning

121 GTGCTGGGAC GAGTCCAGAT GCGGACGCGG CGGACGTTAA GGGGACACCT GGCCAAGATT  
EXON 5

181 TACGCCATGC ACTGGGCCAC TGATTCTAAG CTGCTGGTAA GTGCCTCGCA AGATGGGAAG  
EXON 5 / Beginning EXON 6

241 CTGATCGTGT GGGACAGCTA CACCACCAAC AAGSTGACAG CCATCCCACT GCGCTCCTCC  
EXON 6 / EXON 7

301 TGGGTTCATGA CCTGTGCCTA TGCCCCATCA GGGAACTTTG TGGCATGTGG GGGGCTGGAG  
EXON 7

361 AACATGTGTT CCATCTACAA CCTCAAATCC CGTAGGGGCA ATGTCAAGT CAGCCGGGAG  
EXON 7

421 CTTTCTGCTC ACACAGGTTA TCTCTCTGCG TGCCGCTTCC TGGATGACAA CAATATTGTG  
EXON 7 /EXON 8

**COPIES**

541 GTATTTGTGG GACACACGGG TGA CTGCATG AGCCTGGCTG TGTCTCCTGA CTCCAATCTC

EXON 9

Deletion in Gβ3s2

### Deletion in Gβ3s2

781 CAGGAGCTGA TCTGCTTCTC CCAAGAGAGC ATCATCTGGG GCAATACCTC GGTCTCTT  
EXON 10 polymorphism site acgtc tgt

901 TCCATGAAGT CTGAGCGTGT GGGCATCCTC TCTGGCCACG ATAACAGGGT GAGCTGCCTG  
EXON 10 /Beginning EXON 11 (Intron dzw. 989 bp)

1021 TGGAAGCTGA**g** gaggctggag aaaggggaagt ggaaggcagt gaacacactc agcagcccc  
EXON 11

End of Open Reading Frame B3-3

1081 tgcccgaccc catctcattc aggtgttttc ttctatatcc cgggtgccat tccactaag  
EXON 11

1141 ctttctcctt tgagggcagt ggggagcatg ggactgtgcc ttggggaggc agcatcaggg  
EXON 11

1201 acacaggggc aaagaactgc cccatctcct cccatggcct tcctcccca cagtcctcac  
EXON 11

1261 agcctctccc ttaatgagca aggacaacct gccctcccc agcctttgc agggccagca  
EXON 11

1321 gacttgatgc tgaggcccca ggccctagga ttctccccc agagccacta cttttgtcca  
EXON 11

1381 ggcctgggtg gtatagggcg ttgggacctg tgactatggc tctggcacaa ctagggctct  
EXON 11

1441 ggcctcttc ttattcatgc tttctcctt ttctacctt tttctctcc taagacaect  
EXON 11

1501 gcaataaagt gtagcacctt ggt  
EXON 11 POLY A SITE

FIG. 20 Amino acid sequence of GB3s-2 (Combined production)

atg ggg gag	atg gag	caa ctg	cgt cag	gaa gcg	gag cag	ctc aag aag	48
Met Gly Glu	Met Glu	Gln Leu	Arg Gln	Glu Ala	Glu Gln	Leu Lys Lys	
	5			10		15	
cag att gca	gat gcc	agg aaa	gcc tgt	gct gac	gtt act	ctg gca gag	96
Gln Ile Ala	Asp Ala	Arg Lys	Ala Cys	Ala Asp	Val Thr	Leu Ala Glu	
	20		25			30	
ctg gtg tct	ggc cta	gag gtg	gtg gga	cga gtc	cag atg	cgg acg cgg	144
Leu Val Ser	Gly Leu	Glu Val	Val Gly	Arg Val	Gln Met	Arg Thr Arg	
	35		40		45		
cgg acg tta	agg gga	cac ctg	gcc aag	att tac	gcc atg	cac tgg gcc	192
Arg Thr Leu	Arg Gly	His Leu	Ala Lys	Ile Tyr	Ala Met	His Trp Ala	
	50		55		60		
act gat tct	aag ctg	ctg gta	agt gcc	tcg caa	gat ggg	aag ctg atc	240
Thr Asp Ser	Lys Leu	Leu Val	Ser Ala	Ser Gln	Asp Gly	Lys Leu Ile	
	65		70		75	75	
gtg tgg gac	agc tac	acc acc	aac aag	gtg cac	gcc atc	cca ctg cgc	288
Val Trp Asp	Ser Tyr	Thr Thr	Asn Lys	Val His	Ala Ile	Pro Leu Arg	
	80			85		90	
tcc tcc tgg	gtc atg	acc tgt	gcc tat	gcc cca	tca ggg	aac ttt gtg	336
Ser Ser Trp	Val Met	Thr Cys	Ala Tyr	Ala Pro	Ser Gly	Asn Phe Val	
	95		100			105	
gca tgt ggg	ggg ctg	gac aac	atg tgt	tcc atc	tac aac	ctc aaa tcc	384
Ala Cys Gly	Gly Leu	Asp Asn	Met Cys	Ser Ile	Tyr Asn	Leu Lys Ser	
	110		115		120		
cgt gag ggc	aat gtc	aag gtc	agc cgg	gag ctt	tct gct	cac aca ggt	432
Arg Glu Gly	Asn Val	Lys Val	Ser Arg	Glu Leu	Ser Ala	His Thr Gly	
	125		130		135		
tat ctc tcc	tgc tgc	cgc ttc	ctg gat	gac aac	aat att	gtg acc agc	480
Tyr Leu Ser	Cys Cys	Arg Phe	Leu Asp	Asp Asn	Asn Ile	Val Thr Ser	
	140		145		150	155	
tcg ggg gac	acc acg	tgt gcc	ttg tgg	gac att	gag act	ggg cag cag	528
Ser Gly Asp	Thr Thr	Cys Ala	Leu Trp	Asp ile	Glu Thr	Gly Gln Gln	
	160		165		170	175	
aag act gta	ttt gtg	gga cac	acg ggt	gac tgc	atg agc	ctg gct gtg	576
Lys Thr Val	Phe Val	Gly His	Thr Gly	Asp Cys	Met Ser	Leu Ala Val	
	180			185		190	
tct cct gac	ttc aat	ctc ttc	att tcg	ggg gcc	tgt gat	gcc agt gcc	624
ser Pro Asp	Phe Asn	Leu Phe	Ile Ser	Gly Ala	Cys Asp	Ala Ser Ala	
	195		200			205	

